Please login to the form below

Not currently logged in
Email:
Password:

J&J's profit falls as sales increase

Johnson & Johnson’s third quarter profit for 2011 has fallen 6.3 per cent despite an increase in the US-based pharmaceutical company’s sales performance

Johnson & Johnson's (J&J) third quarter profit for 2011 has fallen 6.3 per cent, with net earnings $3.20bn during the period compared to $3.42bn in 2010.

The dip in profit performance contrasted with the company's sales, which increased by 6.8 per cent to $16.01bn.

However, both the cost of products sold and expenses related to selling, marketing and administration increased significantly between 2010 and 2011 for J&J, with the company also affected by a higher tax rate.

William C Weldon, chairman and CEO of J&J, described the company's performance as “solid” and commended the effect recent product launches have had on revenue.

Regionally, US pharmaceutical sales declined 6.1 per cent, while international sales increased 27.5 per cent to $3.11bn, overtaking the company's revenue in the US.

Sales results in the US were negatively impacted by generic competition for Levaquin (levofloxacin), a treatment for bacterial infections.

A webcast is available concerning J&J's financial results for the third quarter of 2011.

19th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics